Evidence map›Paper›PMID 28469129›Full record

ArticleScientific reports2017

Subventricular zone involvement in Glioblastoma - A proteomic evaluation and clinicoradiological correlation.

Kishore Gollapalli, Saicharan Ghantasala, Sachendra Kumar, Rajneesh Srivastava, Srikanth Rapole, Aliasgar Moiyadi, Sridhar Epari, Sanjeeva Srivastava

Open access · goldAbstract read
In one paragraph

Article in Scientific reports, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 27 papers.

0numbers the graph read from it
0cells of the map it votes in
27citing papers in PubMed
4.3field-weighted citation impact, top 5% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

27 citing papers in PubMed, 40 citations in OpenAlex.

  1. [Development and Evaluation of Prognostic Nomogram Model for Adult Ventricle Glioma Patients].Sichuan da xue xue bao. Yi xue ban = Journal of Sichuan University. Medical science edition · 2022
    Trial
  2. Review
  3. Article
  4. Article
  5. Live Organoid Cyclic Imaging.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2024
    Article
  6. Review
  7. Review
  8. Article
  9. Article
  10. Review
  11. Article
  12. Article
  13. Review
  14. Article
  15. Article
  16. Article
  17. Article
  18. Review
  19. Intraventricular Glioblastoma.The Neurohospitalist · 2019
    Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 3 institutions in 1 country.

Kishore GollapalliDepartment of Biosciences and Bioengineering, IIT Bombay, Mumbai, India.
Saicharan GhantasalaDepartment of Biosciences and Bioengineering, IIT Bombay, Mumbai, India.
Sachendra KumarDepartment of Biosciences and Bioengineering, IIT Bombay, Mumbai, India.
Rajneesh SrivastavaDepartment of Biosciences and Bioengineering, IIT Bombay, Mumbai, India.
Srikanth RapoleProteomics Laboratory, National Centre for Cell Science, Ganeshkhind, Pune, India.
Aliasgar MoiyadiAdvanced Centre for Treatment, Research and Education in Cancer (ACTREC) and Tata Memorial Hospital, Tata Memorial Centre, Kharghar, Navi Mumbai, Mumbai, India.
Sridhar EpariAdvanced Centre for Treatment, Research and Education in Cancer (ACTREC) and Tata Memorial Hospital, Tata Memorial Centre, Kharghar, Navi Mumbai, Mumbai, India.
Sanjeeva SrivastavaDepartment of Biosciences and Bioengineering, IIT Bombay, Mumbai, India. sanjeeva@iitb.ac.in.
Indian Institute of Technology Bombay · INTata Memorial Hospital · INNational Centre for Cell Science · IN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Glioblastoma multiforme (GBM), the most malignant of all gliomas is characterized by a high degree of heterogeneity and poor response to treatment. The sub-ventricular zone (SVZ) is the major site of neurogenesis in the brain and is rich in neural stem cells. Based on the proximity of the GBM tumors to the SVZ, the tumors can be further classified into SVZ+ and SVZ-. The tumors located in close contact with the SVZ are classified as SVZ+, while the tumors located distantly from the SVZ are classified as SVZ-. To gain an insight into the increased aggressiveness of SVZ+ over SVZ- tumors, we have used proteomics techniques like 2D-DIGE and LC-MS/MS to investigate any possible proteomic differences between the two subtypes. Serum proteomic analysis revealed significant alterations of various acute phase proteins and lipid carrying proteins, while tissue proteomic analysis revealed significant alterations in cytoskeletal, lipid binding, chaperone and cell cycle regulating proteins, which are already known to be associated with disease pathobiology. These findings provide cues to molecular basis behind increased aggressiveness of SVZ+ GBM tumors over SVZ- GBM tumors and plausible therapeutic targets to improve treatment modalities for these highly invasive tumors.

Indexed as

Acute-Phase ProteinsBrain NeoplasmsCarrier ProteinsCell Cycle ProteinsCytoskeletal ProteinsGene Expression ProfilingGlioblastomaHumansLateral VentriclesMolecular Sequence AnnotationNeoplasm ProteinsNeoplastic Stem CellsNeural Stem CellsNeurogenesisProteomeAcute-Phase ProteinsCarrier ProteinsCell Cycle ProteinsCytoskeletal Proteinslipid transfer proteinNeoplasm ProteinsProteome

Identifiers

PMID28469129
PMCPMC5431125
OpenAlexW2609595823

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.